Asia stocks drift lower with Fed in focus; Australia falls as RBA rings hawkish
Moderna, Inc. (NASDAQ:MRNA) announced Wednesday that its shareholders approved a one-time stock option exchange program for non-Executive Committee employees. The decision was made during a special meeting of shareholders held on November 12, where a quorum was present.
According to a statement based on a Securities and Exchange Commission filing, the proposal received 231,049,158 votes in favor, 6,167,159 votes against, and 250,409 abstentions.
In addition to the approval of the stock option exchange program, shareholders also approved a proposal to adjourn the special meeting to a later date if necessary. This measure was intended to allow for further solicitation and voting of proxies if there were insufficient votes for the option exchange proposal. The adjournment proposal received 223,991,059 votes for, 13,198,386 votes against, and 277,281 abstentions.
No other matters were submitted or voted on during the special meeting. There were no broker non-votes reported for either proposal.
The information in this article is based on a press release statement and details disclosed in Moderna’s recent SEC filing.
In other recent news, Moderna reported its third-quarter 2025 earnings, surpassing expectations with an earnings per share (EPS) of -0.51, which was significantly better than the forecasted -2.05. The company’s revenue also exceeded projections, reaching $1.02 billion compared to the anticipated $909.97 million. This earnings beat highlights Moderna’s progress in cost reduction, as both the cost of goods sold and research and development spending came in below consensus expectations. Bernstein has maintained its Market Perform rating on Moderna, with a price target of $25.00, acknowledging these developments. Meanwhile, the U.S. Food and Drug Administration appointed Richard Pazdur to lead the Center for Drug Evaluation and Research, a key department responsible for reviewing most new drugs. This move is seen as a positive development for the pharmaceutical sector. These recent developments provide investors with valuable insights into Moderna’s financial performance and regulatory landscape.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.